Medical marijuana use may result in the rapid onset of cannabis use disorder.

Medical marijuana use may result in the rapid onset of cannabis use disorder.

Obtaining a medical marijuana card (MMC) to use cannabis products to treat pain, anxiety, or depression symptoms resulted in the onset of cannabis use disorder (CUD) in a significant minority of individuals while failing to improve their symptoms, according to a study published in JAMA Network Open by researchers at Massachusetts General Hospital (MGH). Researchers discovered that those seeking relief from anxiety and depression were most at risk of developing the addictive symptoms of CUD, implying the need for stronger safeguards over the dispensing, use, and professional follow-up of people who legally obtain cannabis through MMCs.

“There have been many claims about the benefits of medical marijuana for treating pain, insomnia, anxiety, and depression, but there hasn’t been any solid scientific evidence to back them up,” says lead author Jodi Gilman, Ph.D., of MGH’s Center for Addiction Medicine. “We discovered that using cannabis for medical purposes can have negative consequences in this first study of patients randomized to receive medical marijuana cards. People with pain, anxiety, or depression symptoms did not report any improvements, but those with insomnia did.” Individuals with symptoms of anxiety or depression—the most common conditions for which medical cannabis is sought—were the most vulnerable to developing cannabis use disorder, according to Gilman. CUD symptoms include the desire for more cannabis in order to overcome drug tolerance, as well as continued use despite physical or psychological problems caused by cannabis.” I am so happy, my dear friend, so absorbed in the exquisite sense of mere tranquil existence, that I neglect my talents. I should be incapable of drawing a single stroke at the present moment; and yet I feel that I never was a greater artist than now.

“Medical” cannabis has grown in popularity, with 36 states and the District of Columbia commercializing its use (as of December 2021) for a variety of health conditions via medical marijuana cards. These cards require the written approval of a licensed physician, who, under the current system, is typically not the patient’s primary care provider but a “cannabis doctor” who may authorize patients with only a cursory examination, no recommendations for alternative treatments, and no follow-up. Indeed, the medical marijuana industry operates outside of the regulatory framework that governs most fields of medicine.

MGH researchers started their trial in 2017 with 269 adults (average age 37) from the greater Boston area who wanted to get a medical marijuana card. The first group was given MMCs right away, while the second group, which served as a control, was asked to wait 12 weeks before receiving a card. Both groups were followed for a period of 12 weeks. The researchers discovered that the odds of developing CUD were nearly two times higher in the MMC cohort than in the wait list control group, and that by week 12, 10% of the MMC group had developed a CUD diagnosis, rising to 20% in those seeking a card for anxiety or depression.

Gilman is a psychiatry associate professor at Harvard Medical School (HMS). A. Eden Evins, MD, is the Cox Family Professor of Psychiatry at Harvard Medical School.

Gilman is a psychiatry associate professor at Harvard Medical School (HMS). A. Eden Evins, MD, is the Cox Family Professor of Psychiatry at Harvard Medical School.

Medical marijuana use may result in the rapid onset of cannabis use disorder.

Can CBD and cannabis products help with acne and psoriasis? Dermatologists advise buyers to be cautious.

Can CBD and cannabis products help with acne and psoriasis? Dermatologists advise buyers to be cautious.

(HealthDay)— Many people are turning to CBD or cannabis products to treat skin conditions such as acne or rosacea, but researchers warn that research on their safety and effectiveness hasn’t kept up with demand.

When more than 500 adults were polled about their use of CBD (cannabidiol) or marijuana, 17.6 percent said they used an over-the-counter cannabis product to treat skin conditions like acne, psoriasis, rosacea, or eczema without a dermatologist’s recommendation, and even more were interested in trying these products.

CBD is derived from hemp, a close relative of the marijuana plant, but unlike THC (delta-9-tetrahydrocannabinol), the active ingredient in marijuana, CBD does not cause intoxication.

“People are using these products without consulting a doctor, and even those who aren’t using them are curious,” said study author Dr. Adam Friedman, chair of dermatology at the George Washington School of Medicine and Health Sciences in Washington, D.C.

He believes it is time for science to catch up.

Early animal data suggests that these products may aid in the treatment of inflammatory skin diseases. “We know that cannabinoids activate the body’s resolvin pathway, which helps to resolve inflammation,” Friedman explained. “Cannabinoids set the stage for inflammation to resolve and recruit the players critical to cleaning up the damage caused by inflammation.”

Approximately 89 percent of people believe marijuana or other cannabis products have a role in the treatment of skin disease, and the majority said they would be willing to try one of these products if their dermatologist gave them the go-ahead.

Can CBD and cannabis products help with acne and psoriasis? Dermatologists advise buyers to be cautious.

According to research, medicinal cannabis products can help with depression and improve overall quality of life.

According to research, medicinal cannabis products can help with depression and improve overall quality of life.

A group of researchers from various institutions in the United States discovered evidence that medicinal cannabis products relieve depression and improve quality of life. The group describes their study involving online surveys about the benefits of cannabis products in their paper published in the journal Frontiers in Psychiatry.

Previous research findings on the use of cannabis-based products to treat depression and anxiety were conflicting. Some patients have made progress, while others have not. Prior research has also discovered that other drugs developed to treat depression and anxiety have mixed results—some patients have seen improvements while others have not, and some patients have discovered that they are unable to tolerate the side effects of the drugs. Furthermore, regardless of the research track record, some people have begun using medicinally approved cannabis products to help with their depression, anxiety, chronic pain, or sleep disorder—either independently or with the assistance of a doctor. Rather than focusing on reports from the medical community about how well these products worked, the researchers conducted a study to gauge the opinions of people who use them.

The research was conducted over a four-year period. At the start, the researchers received responses from 368 people who said they used cannabis products to relieve depression and/or anxiety or to sleep better. As a control group, they also received responses from 170 people who did not use cannabis products but were considering doing so due to depression or anxiety issues.

The researchers discovered that people who used cannabis products (mostly those containing CBD rather than THC) had lower levels of depression than the control group, but no difference in anxiety. They also discovered that those who used cannabis products had a higher quality of life and slept better than the control group. The researchers also discovered lower levels of depression in those who continued to use cannabis products as well as those who started using them during the study. Intriguingly, they discovered that those who started using the products during the study reported improvements in anxiety and quality of life.

According to research, medicinal cannabis products can help with depression and improve overall quality of life.

According to research, medicinal cannabis products can help with depression and improve overall quality of life. According to research, medicinal cannabis products can help with depression and improve overall quality of life. marijuanamania420 marijuanamania420According to research, medicinal cannabis products can help with depression and improve overall quality of life. marijuanamania420According to research, medicinal cannabis products can help with depression and improve overall quality of life.
Packaging and health warnings are critical in discouraging youth use of cannabis.

Packaging and health warnings are critical in discouraging youth use of cannabis.

As more countries consider legalizing non-medical cannabis, new research suggests that prominent health warnings and less appealing packaging should be required to reduce the appeal of cannabis to children.

Researchers from the University of Waterloo discovered in a recent study that the amount of advertising and promotion provided on packages affects how people perceive the product—whether they think it’s fun to use, are interested in trying it, or believe it’s harmful.

“For a child entering the market and trying to figure out if cannabis is a product their friends would think is cool, and that they can project an image with it, that’s exactly what brand imagery and promotion does, especially on packages,” said David Hammond, a professor in the School of Public Health Sciences at the University of Waterloo. “As a result, if states or countries want to protect youth, our data suggest that packaging restrictions and comprehensive health warnings are effective ways to do so.”

“The more imagery legislators permit, the more appealing these cannabis products will be to the general public, particularly children.” It is up to governments to determine where the line should be drawn.”

The team of researchers gathered input from 45,378 randomized participants in Canada and the United States to determine the effectiveness of restricted brand imagery and information from governments in the form of health warnings on how cannabis products are perceived. Four branding conditions were presented to the participants, ranging from no brand imagery and uniform colors to full brand imagery. They were also asked to rate how appealing the products were based on perceived harm and how easy it is to remember warning messages about pregnancy, adolescent risk, and impaired driving.

The researchers discovered that reducing the amount of brand imagery had a minor impact on product appeal. Furthermore, when products had a white background with no or limited branding, they were rated significantly less harmful than when they had a colored background, and message recall was significantly higher for Canadian versus US health warnings.

“Canada’s warning messages on cannabis products are more visible and understandable than in the United States,” Hammond said. “Our findings also indicate that Canada’s comprehensive regulations appear to be achieving their goal of informing consumers about risks and reducing appeal, particularly among young people.”

The study, Influence of package color, branding, and health warnings on the appeal and perceived harm of cannabis products among respondents in Canada and the United States, will be published in the journal Preventive Medicine by Hammond, Samantha Goodman, Vicki Rynard, and Maryan Iraniparast.

Packaging and health warnings are critical in discouraging youth use of cannabis.

Is medical marijuana an effective treatment for childhood epilepsy?

Is medical marijuana an effective treatment for childhood epilepsy?

Following media reports of children with epilepsy allegedly benefiting from medical marijuana (or cannabis-based medicinal products) obtained abroad, the UK government granted clinicians the authority to prescribe these products. A review published in Developmental Medicine & Child Neurology investigates the science behind cannabis-based medicinal products in pediatric epilepsies and identifies areas that require further investigation.

The authors also looked into the prescribing environment for these products. They discovered that the main barrier to prescribing is a lack of high-quality evidence for efficacy and safety.

They emphasize that unlicensed cannabis-based medicinal products should not be prescribed unless they meet standard regulatory requirements. They are also concerned that children with epilepsy may be used as a “Trojan horse” for the cannabis industry, with widespread acceptance of medicinal cannabis hastening the legalization of marijuana and opening up a lucrative commercial market.

Is medical marijuana an effective treatment for childhood epilepsy?

Cannabis intoxication and accidental ingestion rates in young children rise after legalization, according to a new study.

Cannabis intoxication and accidental ingestion rates in young children rise after legalization, according to a new study.

Following the drug’s legalization in Canada, there has been a significant increase in the number of children admitted to intensive care for unintentional cannabis poisonings.

In the first two years after cannabis legalization, researchers from The Hospital for Sick Children (SickKids) in Toronto discovered a four-fold increase in unintentional poisonings in children under the age of 12 and a three-fold increase in intensive care admissions for severe cannabis poisoning.

When comparing the pre- and post-legalization periods, the overall number of visits per month for cannabis intoxications to the SickKids Emergency Department (ED) remained consistent. Clinical Toxicology, a peer-reviewed journal, published the findings.

The study compared cannabis-related ED visits, hospitalizations, and intensive care unit (ICU) admissions at SickKids during pre- and post-legalization periods to analyze the unintended consequences of the legislation, led by Dr. Yaron Finkelstein, Staff Physician, Paediatric Emergency Medicine and Clinical Pharmacology and Toxicology at SickKids.

“While cannabis intoxication is uncommon in adults, it can have serious consequences for young children, including behavioral changes, seizures, respiratory depression, coordination and balance problems, and even coma. As various cannabis formulations become legal, it is critical for everyone who has cannabis in their home to be aware of the potential harms to children and to ensure cannabis products are safely stored “Finkelstein, SickKids’ Senior Scientist, Child Health Evaluative Sciences.

Measuring admissions for cannabis intoxication to SickKids over a 12-year period, from January 1, 2008 to December 31, 2019, the study discovered that after legalization, a higher proportion of children were admitted to the ICU (13.6 percent vs. 4.7 percent , respectively).

The study determined that the rise in severe cannabis intoxications was primarily due to young children’s exposure to cannabis edibles, which have become increasingly accessible and popular. Because edible cannabis products are both highly concentrated and visually appealing to young children, ingestion is the most significant route of paediatric exposure. Inconsistencies and difficulties in determining the precise formulation and potency of the edible consumed can also make it difficult for health-care providers to predict the severity and duration of the effects of cannabis exposure.

The study team, which included researchers and trainees from across SickKids, hopes that by raising awareness of the potential dangers of unintentional cannabis poisonings, the findings will encourage the public to be even more cautious when storing cannabis products at home, particularly edibles, which are frequently mistaken for regular food and candy by children.

“Because the COVID-19 pandemic has provided more opportunities for families to stay at home, it is even more important to keep substances like cannabis out of the reach of young children. There are simple steps that everyone can take to help prevent unintentional poisonings and keep children safe, such as storing cannabis products in a locked container separate from other food and drinks “Finkelstein, who is also a Professor at the University of Toronto’s Departments of Paediatrics, Pharmacology, and Toxicology, adds.

Cannabis intoxication and accidental ingestion rates in young children rise after legalization, according to a new study.

Is there a new high for migraine treatment? The trial investigates the efficacy of THC and CBD.

Is there a new high for migraine treatment? The trial investigates the efficacy of THC and CBD.

Allison Knigge began having migraines when she was in elementary school. They became progressively worse over time, particularly after the birth of her son.

“My migraines are described as piercing pain. It’s as if my mind is being squeezed. It causes extreme sensitivity to light and sound, as well as horrendous nausea “Knigge stated. “I’ve experienced pain levels of 6 or higher for approximately 25 days out of the month. They have an impact on my quality of life.”

Migraines cause symptoms that are frequently severe and incapacitating. They cause severe throbbing or pulsating headaches, usually on one side of the head, and are frequently accompanied by nausea, vomiting, and/or extreme sensitivity to light and sound. A migraine attack can last for hours, days, or even weeks.

Knigge claims she has tried a number of medications over the years, but none have been able to completely relieve her migraines.

“The weather, stress, and a lack of sleep all contribute to my migraines. When the pain becomes unbearable, I spend the entire day in bed, with the lights turned off “Knigge stated. “When I have a migraine, I am completely incapacitated, which is difficult as a mother.”

Despite the fact that there are numerous FDA-approved treatments on the market, experts say that many patients are turning to cannabis products containing THC and/or CBD, a non-psychoactive component of cannabis, to treat their migraines.

“Many migraine patients have been suffering from them for many years but have never discussed them with their doctors. They are, instead, self-medicate with various treatments such as cannabis “said Nathaniel Schuster, MD, UC San Diego Health’s pain management specialist and headache neurologist, and investigator at the UC San Diego Center for Medicinal Cannabis Research. “Right now, we don’t have evidence-based data to answer patients’ questions about whether cannabis works for migraines.”

Schuster and his colleagues at UC San Diego Health are conducting the first known randomized, double-blind, placebo-controlled clinical trial of cannabis as a potential treatment for acute migraines.

A total of 20 people are currently enrolled in the clinical trial. Knigge is among them.

“I decided to take part in the trial after hearing about it from Dr. Schuster. I had reached a point where I was willing to try anything to help me manage my migraines “Knigge stated.

The goal is to enroll 90 participants who will be randomized to receive four different treatments for four separate migraine attacks: one with THC, one with CBD, one with a combination of the two, and one with a placebo. A vaporizer is used to administer the products.

“Vaporized cannabis may be more effective for patients who have nausea or gastrointestinal issues with their migraines,” said Shuster, an assistant professor in the Department of Anesthesiology at the University of California, San Diego.

To be eligible for the clinical trial, patients must have migraines at least once a month, be a non-regular cannabis user, not use opioids, and be between the ages of 21 and 65.

“I am proud and grateful to be a part of a study that may result in more tools in the toolbox for those of us who suffer from migraines,” Knigge said. “It could mean that you have one more option if all of your other options have failed. This is extremely important for patients whose lives are regularly disrupted by migraines.”

Schuster stated that future research would compare different cannabinoid doses.

Is there a new high for migraine treatment? The trial investigates the efficacy of THC and CBD.

migraine treatment migraine treatment marijuanamania420migraine treatment marijuanamania420migraine treatment marijuanamania420migraine treatment
Medical cannabis can alleviate essential tremor by activating previously unnoticed cells in the central nervous system.

Medical cannabis can alleviate essential tremor by activating previously unnoticed cells in the central nervous system.

Medical cannabis is a hotly debated topic. There is still much we don’t know about cannabis, but researchers from the Faculty of Health and Medical Sciences’ Department of Neuroscience have made a new discovery that could be critical to future medical cannabis research and treatment.

Cannabinoids are chemical compounds found in cannabis as well as the central nervous system. The researchers used a mouse model to show that a specific synthetic cannabinoid (cannabinoid WIN55,212-2) reduces essential tremor by activating spinal cord and brain support cells known as astrocytes. Previous research into medical cannabis has concentrated on nerve cells, or neurons.

“We concentrated on the disease essential tremor. It causes involuntary shaking, which can be extremely inhibiting and have a serious impact on the patient’s quality of life. However, the cannabinoid may have a beneficial effect on multiple sclerosis and spinal cord injuries, both of which cause involuntary shaking “According to the project’s leader, Associate Professor Jean-François Perrier of the Department of Neuroscience.

“We discovered that injecting the cannabinoid WIN55,212-2 into the spinal cord activates the astrocytes and causes them to release the substance adenosine, which reduces nerve activity and thus the unwanted shaking.”

Treatment that is specific and does not have any negative side effects

The discovery that astrocytes are involved in the explanation for cannabis’s effect is a completely novel approach to understanding cannabis’s medical effects, and it may help improve the treatment of patients suffering from involuntary shaking.

The spinal cord is in charge of the majority of our movements. When the motor neurons in the spinal cord are activated, both voluntary and spontaneous movements are elicited. Motor neurons connect the spinal cord to the muscles, and when a motor neuron sends an impulse to the muscles, it causes contraction and thus movement. When motor neurons send out conflicting signals at the same time, involuntary shaking occurs. That is why the researchers have concentrated their efforts on the spinal cord.

“One could imagine a new approach to medical cannabis for shaking, where you—during the development of cannabis-based medicinal products—target the treatment either at the spinal cord or the astrocytes—or, at best, the astrocytes of the spinal cord,” says Postdoc Eva Carlsen, who performed the majority of the tests during her Ph.D. and postdoc projects.

“By taking this approach, we will avoid affecting the neurons in the brain that are responsible for our memory and cognitive abilities, and we will be able to offer effective treatment to patients suffering from involuntary shaking without exposing them to any of the most problematic side effects of medical cannabis.”

The next step will be to conduct clinical trials on patients suffering from essential tremor to see if the new approach has the same effect in humans.

The study, titled Spinal astroglial cannabinoid receptors regulate pathological tremor, was published in the journal Nature Neuroscience.

Medical cannabis can alleviate essential tremor by activating previously unnoticed cells in the central nervous system.

According to one study, using cannabis

According to one study, using cannabis while trying to conceive may reduce your chances of getting pregnant.

Reproduction in Humans According to a study conducted by researchers at the National Institutes of Health, women who use marijuana may have a more difficult time conceiving a child than women who do not use marijuana. Marijuana use among the women’s partners was not investigated, which could have influenced conception rates. Sunni L. Mumford, Ph.D., of the Epidemiology Branch at the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, led the team. The research was published in the journal Human Reproduction.

The women were part of a larger group of women who were attempting to conceive after one or two previous miscarriages. Women who reported using cannabis products—marijuana or hashish—in the weeks preceding pregnancy, or who had positive urine tests for cannabis use, were approximately 40% less likely to conceive per monthly cycle than women who did not use cannabis. Although the findings suggest that cannabis may affect women’s fertility, the authors cautioned that they should be interpreted with caution because the study only included a small number of cannabis users. However, the authors state that their findings suggest that women who are trying to conceive should use cannabis with caution until more conclusive evidence is available.

The researchers examined data from a larger study of over 1,200 women ages 18 to 40 who had one or two miscarriages. The women took part in the study for up to six monthly cycles while attempting to conceive and for the duration of the pregnancy if conception occurred. Following enrollment in the study, the women completed a questionnaire in which they were asked if they had used marijuana, pot, or hashish in the previous 12 months, with responses ranging from never, rarely, occasionally, sometimes, frequently, to daily. Each woman also provided urine samples for analysis when she first entered the study, six months later if she did not conceive, and at the time of a positive pregnancy test if she did conceive.

For each monthly cycle, women who had used cannabis while trying to conceive were 41% less likely to conceive than non-users. Similarly, a smaller proportion of cannabis users than non-users became pregnant during the study—42% versus 66%. The authors found no differences in miscarriage rates between users and non-users who had achieved pregnancy.

The authors noted that, compared to non-users, cannabis users also had differences in reproductive hormones involved in ovulation. These differences could potentially have influenced their likelihood of conception. Specifically, users had higher levels of luteinizing hormone and a higher proportion of luteinizing hormone to follicle stimulating hormone.

The authors also mentioned that animal studies had revealed that cannabis use could alter the uterine lining, making it less likely that an embryo would implant and establish a pregnancy. Women trying to conceive should be aware that cannabis may have an effect on their pregnancy chances until more research is available, according to the authors.

According to one study, using cannabis

According to one study, using cannabis According to one study, using cannabis marijuanamania420According to one study, using cannabis marijuanamania420According to one study, using cannabis marijuanamania420
More than half of those who use cannabis for pain have multiple withdrawal symptoms.

More than half of those who use cannabis for pain have multiple withdrawal symptoms.

A new study finds that more than half of people who use medical marijuana products to relieve pain also experience clusters of multiple withdrawal symptoms when they stop using them.

Over the next two years, about 10% of the patients in the study experienced worsening changes in their sleep, mood, mental state, energy, and appetite as they continued to use cannabis.

Many of them may be unaware that their symptoms are caused by their brain and body’s reaction to the lack of substances in the cannabis products they’re smoking, vaping, eating, or applying to their skin, according to the University of Michigan Addiction Center psychologist who led the study.

When a person experiences more than a few of these symptoms, this is referred to as cannabis withdrawal syndrome, and it can indicate a higher risk of developing more serious issues, such as a cannabis use disorder.

A team from the University of Michigan Medical School and the VA Ann Arbor Healthcare System reports findings from detailed surveys of 527 Michigan residents conducted over a two-year period in the journal Addiction. All were involved in the state’s system for certifying people with certain conditions for the use of medical cannabis, and all were suffering from non-cancer-related pain.

“Some people report significant benefits from medical cannabis,” says Lara Coughlin, Ph.D., the addiction psychologist who led the study. “However, our findings suggest a real need to raise awareness about the signs of withdrawal symptoms developing in order to reduce the potential downsides of cannabis use, particularly among those who experience severe or worsening symptoms over time.”

Long-term research into medical cannabis use

The researchers asked the patients if they had experienced any of 15 different symptoms, ranging from difficulty sleeping and nausea to irritability and aggression, after being away from cannabis for an extended period of time.

The researchers used an analytic method to empirically categorize the patients as having no or mild symptoms at the start of the study, moderate symptoms (meaning they experienced multiple withdrawal symptoms), and severe withdrawal issues that included most or all of the symptoms.

title